The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 36.15%.However, over the last six months, we can see a stronger performance of -42.30%. Over the last 30 days, the price of NEUP has fallen by 53.76%. And in the last five days, it has surged by 48.25%.
The stock market performance of Neuphoria Therapeutics Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $16.08 on 02/14/24, while the lowest price during the same time frame was $2.12, recorded on 10/28/24.
52-week price history of NEUP Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Neuphoria Therapeutics Inc’s current trading price is -70.96% away from its 52-week high, while its distance from the 52-week low is 119.87%. The stock’s price range for this period has been between $2.12 and $16.08. The Healthcare sector company’s shares saw a trading volume of about 0.84 million for the day, which was lower than the average daily volume of 1.29 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Neuphoria Therapeutics Inc (NEUP) has experienced a quarterly rise of 32.46% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.42M and boasts a workforce of 24 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 4.31, with a change in price of -3.04. Similarly, Neuphoria Therapeutics Inc recorded 818,435 in trading volume during the last 100 days, posting a change of -39.43%.
NEUP’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for NEUP stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
NEUP Stock Stochastic Average
As of today, the raw stochastic average of Neuphoria Therapeutics Inc over the past 50 days is 19.45%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 18.34%. Additionally, the Stochastic %K and %D values for the company were 13.85% and 10.50%, respectively, over the past 20 days.
